Prostamax

Also known as: Lys-Glu-Asp-Pro

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA

Randomized controlled trials 0 of 5 publications on PubMed

Registered clinical trials 0 0 active

Adverse event reports 0 0 classified as serious

Prostamax is not an FDA-approved drug: Drugs@FDA has no record of it.
PubMed lists 5 publications mentioning it, including 0 randomized controlled trials and 1 animal-only study.
No study registered on ClinicalTrials.gov tests it as an intervention.
FDA’s adverse event system (FAERS) has no reports mentioning it.

Research topics

Lymphocytes 4
Aging 3
Heterochromatin 3
Calorimetry, Differential Scanning 2
Nucleic Acid Denaturation 2
Cadmium 1
Chromatin 1
Copper 1
Heart 1
Lung 1

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 5
Human (MeSH) 4
Animal only 1
Clinical trials 0
Randomized controlled trials 0
Systematic reviews & meta-analyses 0
Case reports 0
Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]. Human study 2012 Georgian medical news
Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax. Human study 2009 Georgian medical news
[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Animal study 2006 Advances in gerontology = Uspekhi gerontologii
[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]. Human study 2004 Biofizika
Effects of short peptides on lymphocyte chromatin in senile subjects. Human study 2004 Bulletin of experimental biology and medicine

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

No registered study on ClinicalTrials.gov lists this peptide as an intervention.

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

No FAERS reports mention this peptide.

Source: FDA FAERS · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.